Released Nov 8, 2018, before the open
10-Q filed Nov 8, 2018, 39 days after period end · 0001144204-18-058118
Q3 2018 · 10-Q
Revenue$4.29M$4.29M +61.1% vs Q3 2017+33.2% vs Q2 2018
Net Income-$21.54M-$21.54M N/M vs Q3 2017N/M vs Q2 2018
EPS Diluted-$0.87-$0.87 N/M vs Q3 2017N/M vs Q2 2018
Operating Income-$22,575,000N/M
Operating Cash Flowderived-$16,684,000N/M
Free Cash Flowderived-$16,721,000N/M
Margins · derived
Operating margin-526.7%−58.6 pt vs Q3 2017
Net margin-502.5%−41.0 pt vs Q3 2017
What the release said
The release
Same quarter
| Metric | Q3 2018 | Q3 2017 | Q3 2016 | Q3 2015 |
|---|---|---|---|---|
| Revenue | $4.29M | $2.66M | — | — |
| Net Income | -$21.54M | -$12.27M | -$11.57M | -$6.62M |
| EPS Diluted | -$0.87 | -$710.00 | -$0.67 | -$0.38 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR